4//SEC Filing
SALZMAN BARRY M 4
Accession 0001104659-25-054695
CIK 0001651407other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 11:20 AM ET
Size
7.1 KB
Accession
0001104659-25-054695
Insider Transaction Report
Form 4
SALZMAN BARRY M
Director
Transactions
- Disposition from Tender
COMMON STOCK
2025-05-30−147,007→ 0 total - Award
COMMON STOCK
2025-05-28+12,195→ 147,007 total
Footnotes (2)
- [F1]Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Salzman's continued service on the board.
- [F2]Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.
Documents
Issuer
Checkpoint Therapeutics, Inc.
CIK 0001651407
Entity typeother
Related Parties
1- filerCIK 0001432179
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 11:20 AM ET
- Size
- 7.1 KB